GA-AGCO
5.5.2022 16:02:11 CEST | Business Wire | Press release
The AGCO Agriculture Foundation (AAF) , a private foundation with the vision to prevent and relieve hunger through sustainable agricultural development, today announced a $50,000 donation to an initiative called "BORSCH" implemented by the Land Club, a non-profit organization in Ukraine. The donation will help "BORSCH" contribute to Ukraine's food and nutrition security during this crisis and improve the livelihoods of Ukrainian farming communities affected by the war.
Expanding on the AAF Ukraine Humanitarian Aid program, the AAF donation to the "BORSCH" initiative will contribute to the purchase of so-called “borsch set” vegetable seeds, namely cabbages, carrots, onions, beetroots, and potatoes. The seeds will be distributed freely to farmers for the planting season in the war-affected areas in Ukraine where they are not now available and accessible.
This donation builds on the Ukraine Humanitarian Aid program the AAF launched in March to support Ukraine with food supplies and ensure the safety of all Ukrainian colleagues and their families. As part of that immediate response, the AAF donated $100,000 to the United Nations World Food Programme (WFP) to provide immediate emergency food assistance. In addition, the AAF established the ongoing ‘AGCO Ukraine Emergency Relief' ShareTheMeal team campaign with WFP to donate and give lifesaving food to those affected by the conflict in Ukraine.
"During this crisis, our priority has been to support farmers and their communities with essential resources," said Metti Richenhagen, Director for the AAF. "Through our Ukraine Humanitarian Aid Program, we are committed to supporting farmer-focused initiatives like ‘BORSCH,’ which helps to ensure that this humanitarian crisis does not become a hunger and food insecurity crisis for farming communities and families."
In Ukraine, the borsch set vegetables are primarily grown in local gardens totaling 3 million hectares of land and benefiting 3.5 million farming households. The initiative distributes seeds to Ukrainian farmers with up to 1 hectare of cultivated farmland, enabling them to produce nutritious food while generating additional income.
"The situation in Ukraine is already negatively impacting sustainable food systems," said Frederic Devienne, Vice President, EME, EME Regional Lead, and Board Member of AGCO Agriculture Foundation. "Putting farmers first to sustainably feed our world is core to our purpose and European operations, and we want to help our farmers and customers in Ukraine continue to keep food production running during the crisis.”
Giving Hope through ShareTheMeal Donation
With over 27,000 meals donated so far, we expand on our meal target. To join AGCO and its Foundation in providing food assistance in Ukraine, visit the "AGCO Ukraine Emergency Relief " ShareTheMeal challenge or download the U.N. World Food Programme ShareTheMeal app on Google Play or App Store . Once installed, join the "AGCO Ukraine Emergency Relief " team challenge to provide food assistance to families in Ukraine through the U.N. World Food Programme. Through your generous donation, we can reach and feed more people within Ukraine and its borders.
About AGCO
AGCO (NYSE:AGCO) is a global leader in the design, manufacture and distribution of agricultural machinery and precision ag technology. AGCO delivers customer value through its differentiated brand portfolio including core brands like Challenger®, Fendt®, GSI®, Massey Ferguson® and Valtra®. Powered by Fuse® smart farming solutions, AGCO's full line of equipment and services help farmers sustainably feed our world. Founded in 1990 and headquartered in Duluth, Georgia, USA, AGCO had net sales of $11.1 billion in 2021. For more information, visit www.AGCOcorp.com . For company news, information and events, please follow us on Twitter: @AGCOCorp. For financial news on Twitter, please follow the hashtag #AGCOIR.
About the AGCO Agriculture Foundation (AAF)
The AGCO Agriculture Foundation (AAF), initiated by AGCO Corporation (NYSE: AGCO) in 2018, is a private foundation with the vision to prevent and relieve hunger. The foundation initiates impactful programs that support food security, foster sustainable agricultural development and build needed agricultural infrastructure in marginalized farming communities. AAF is domiciled in Vaduz, Liechtenstein and operations are managed from Duluth, Georgia, USA. For more information, please visit https://www.agcofoundation.org/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220427005230/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom